Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
暂无分享,去创建一个
Alessandro Filippi | Gianni Tognoni | G. Tognoni | A. Nicolucci | M. Sacco | V. Evangelista | Antonio Nicolucci | Giorgia De Berardis | Michele Sacco | Umberto Valentini | C. Giorda | A. Filippi | Virgilio Evangelista | Carlo B Giorda | G. de Berardis | U. Valentini
[1] G. Tognoni,et al. Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin , 2004, Thrombosis and Haemostasis.
[2] J. Manson,et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.
[3] A. Blann,et al. Increased Levels of Soluble Adhesion Molecules in Type 2 (Non-Insulin Dependent) Diabetes mellitus Are Independent of Glycaemic Control , 1994, Thrombosis and Haemostasis.
[4] N Rifai,et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.
[5] M. Roncaglioni,et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. , 2003, Diabetes care.
[6] M. Halushka,et al. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? , 2002, Circulation.
[7] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[8] V. Salomaa,et al. Impact of Diabetes on Mortality After the First Myocardial Infarction , 1998, Diabetes Care.
[9] S. Yusuf,et al. Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.
[10] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .
[11] A. Vinik,et al. Platelet dysfunction in type 2 diabetes. , 2001, Diabetes care.
[12] K. Lam,et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. , 2002, The Journal of clinical endocrinology and metabolism.
[13] J. Liao. Beyond lipid lowering: the role of statins in vascular protection. , 2002, International journal of cardiology.
[14] P. Ridker. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.
[15] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[16] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[17] A. Mattioli,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[18] T. Kishimoto,et al. Circulating Vascular Cell Adhesion Molecule-1 (VCAM-1) in Atherosclerotic NIDDM Patients , 1997, Diabetes.
[19] S. Haffner. Coronary heart disease in patients with diabetes. , 2000, The New England journal of medicine.
[20] A. Rebuzzi,et al. Heterogeneity in the suppression of platelet cyclooxygenase‐1 activity by aspirin in coronary heart disease , 2006, Clinical pharmacology and therapeutics.
[21] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[22] J. Hippisley-Cox,et al. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis , 2005, BMJ : British Medical Journal.
[23] T. Hedner,et al. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.
[24] G. Gaetano,et al. Drink in moderation, says consensus panel , 2001, The Lancet.
[25] G. de Gaetano. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. , 2001, Lancet.
[26] I. Vucenik,et al. Platelet responsiveness to aspirin in patients with hyperlipidaemia , 2003, BMJ : British Medical Journal.
[27] Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. , 2002, The Journal of clinical endocrinology and metabolism.
[28] S. Anand. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Eikelboom JW, Hirsh J, Weitz J, Johnston M, Yi Q, Yusuf S. Circulation 2002; 105: 1650- 1655. , 2002 .
[29] Sandeep Vijan,et al. Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians , 2004, Annals of Internal Medicine.
[30] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[31] N J Wald,et al. A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.
[32] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[33] M. Roncaglioni. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.
[34] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[35] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[36] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .